Mandar A Aras1, Mitchell A Psotka2, Teresa De Marco3. 1. Division of Cardiology, University of California San Francisco, 505 Parnassus Avenue, Box 0124, San Francisco, CA, 94143, USA. 2. Inova Heart and Vascular Institute, Falls Church, VA, USA. 3. Division of Cardiology, University of California San Francisco, 505 Parnassus Avenue, Box 0124, San Francisco, CA, 94143, USA. Teresa.DeMarco@ucsf.edu.
Abstract
PURPOSE OF REVIEW: Pulmonary hypertension (PH) frequently complicates heart failure and portends a worse prognosis. This review will summarize and discuss recent updates in the classification and management of patients with PH due to left heart disease. RECENT FINDINGS: Careful hemodynamic assessment is critical to the classification of patients with PH and heart failure. Two hemodynamic subgroups of PH in heart failure patients have been described: isolated post-capillary pulmonary hypertension and combined post- and precapillary pulmonary hypertension. The cornerstone in management of PH due to left heart disease is the treatment of the underlying left heart pathology; however, ongoing trials have been designed to test pulmonary vasodilators in this cohort. PH-specific therapies have not demonstrated a benefit in patients with pulmonary hypertension due to left heart disease. Understanding the distinct pathobiology of each hemodynamic subgroup may lead to the development of useful biomarkers and effective targeted therapies.
PURPOSE OF REVIEW: Pulmonary hypertension (PH) frequently complicates heart failure and portends a worse prognosis. This review will summarize and discuss recent updates in the classification and management of patients with PH due to left heart disease. RECENT FINDINGS: Careful hemodynamic assessment is critical to the classification of patients with PH and heart failure. Two hemodynamic subgroups of PH in heart failurepatients have been described: isolated post-capillary pulmonary hypertension and combined post- and precapillary pulmonary hypertension. The cornerstone in management of PH due to left heart disease is the treatment of the underlying left heart pathology; however, ongoing trials have been designed to test pulmonary vasodilators in this cohort. PH-specific therapies have not demonstrated a benefit in patients with pulmonary hypertension due to left heart disease. Understanding the distinct pathobiology of each hemodynamic subgroup may lead to the development of useful biomarkers and effective targeted therapies.
Entities:
Keywords:
HFpEF; Heart failure; Left heart disease; Post-capillary; Pulmonary hypertension; WHO group 2 pulmonary hypertension
Authors: Mandeep R Mehra; Charles E Canter; Margaret M Hannan; Marc J Semigran; Patricia A Uber; David A Baran; Lara Danziger-Isakov; James K Kirklin; Richard Kirk; Sudhir S Kushwaha; Lars H Lund; Luciano Potena; Heather J Ross; David O Taylor; Erik A M Verschuuren; Andreas Zuckermann Journal: J Heart Lung Transplant Date: 2016-01 Impact factor: 10.247
Authors: Yogesh N V Reddy; Rickey E Carter; Masaru Obokata; Margaret M Redfield; Barry A Borlaug Journal: Circulation Date: 2018-08-28 Impact factor: 29.690
Authors: Robert Naeije; Mario Gerges; Jean-Luc Vachiery; Sergio Caravita; Christian Gerges; Irene M Lang Journal: Circ Heart Fail Date: 2017-09 Impact factor: 8.790
Authors: Mads J Andersen; Thomas P Olson; Vojtech Melenovsky; Garvan C Kane; Barry A Borlaug Journal: Circ Heart Fail Date: 2014-10-23 Impact factor: 8.790
Authors: James C Fang; Teresa DeMarco; Michael M Givertz; Barry A Borlaug; Gregory D Lewis; J Eduardo Rame; Mardi Gomberg-Maitland; Srinivas Murali; Robert P Frantz; Dana McGlothlin; Evelyn M Horn; Raymond L Benza Journal: J Heart Lung Transplant Date: 2012-09 Impact factor: 10.247
Authors: Gregory D Lewis; Debby Ngo; Anna R Hemnes; Laurie Farrell; Carly Domos; Paul P Pappagianopoulos; Bishnu P Dhakal; Amanda Souza; Xu Shi; Meredith E Pugh; Arkadi Beloiartsev; Sumita Sinha; Clary B Clish; Robert E Gerszten Journal: J Am Coll Cardiol Date: 2016-01-19 Impact factor: 24.094
Authors: Ahmed U Fayyaz; William D Edwards; Joseph J Maleszewski; Ewa A Konik; Hilary M DuBrock; Barry A Borlaug; Robert P Frantz; Sarah M Jenkins; Margaret M Redfield Journal: Circulation Date: 2017-12-15 Impact factor: 29.690
Authors: Tufik R Assad; Bradley A Maron; Ivan M Robbins; Meng Xu; Shi Huang; Frank E Harrell; Eric H Farber-Eger; Quinn S Wells; Gaurav Choudhary; Anna R Hemnes; Evan L Brittain Journal: JAMA Cardiol Date: 2017-12-01 Impact factor: 14.676
Authors: James C Coons; Kristen Pogue; Andrew R Kolodziej; Glenn A Hirsch; Marjorie Patricia George Journal: Curr Cardiol Rep Date: 2019-11-22 Impact factor: 2.931